Promega Corporation Release: New Report Further Demonstrates Ultra-Glo™ Luciferase is Less Susceptible to Compound Interference

MADISON, Wis.--(BUSINESS WIRE)--Research results just published in the Journal of Medicinal Chemistry demonstrate the superior performance of Promega Ultra-Glo™ Luciferase. The research, conducted by the NIH Chemical Genomics Center (NCGC), describes Ultra-Glo recombinant luciferase as approximately 90% less susceptible to small molecule inhibition compared to another commercially available luciferase. The NCGC is leading the US government-sponsored efforts aimed at developing biological probes and expanding the use of HTS assays in academic settings.
MORE ON THIS TOPIC